She is leading a clinical trial testing the combination of LMB-100, a drug developed in CCR by the Pastan Lab that is designed to kill cancer cells, and nab-paclitaxel, a drug used to treat … Pancreatic cancer can form in exocrine cells and neuroendocrine cells. PD-L1 amplified tumors 50. The following are some of our latest news articles on pancreatic cancer research: View the full list of Pancreatic Cancer Research Results and Study Updates. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. When either of these genes is mutated, or altered, such that its protein product is not made or does not function correctly, DNA damage may not be repaired properly. The study objectives are to assess the safety, tolerability and pharmacokinetics (PK) of the oral RAD51 inhibitor CYT-0851 in patients with relapsed / refractory B-cell malignancies and advanced solid tumors and to identify a recommended Phase 2 dose for evaluation in these patients. Pancreatic neuroendocrine tumors are less common but have a better prognosis. Pheochromocytoma, malignant (closed to accrual) 25. Location: 21 locations, The purpose of this study is to evaluate the dose, safety, immunogenicity and early clinical activity of GRT-C903 and GRT-R904, a neoantigen-based therapeutic cancer vaccine, in combination with immune checkpoint blockade, in patients with advanced or metastatic non-small cell lung cancer, microsatellite stable colorectal cancer, pancreatic cancer, and shared neoantigen-positive tumors. Non-epithelial tumors of the ovary: A) Germ cell tumor of ovary B) Mullerian mixed tumor and adenosarcoma (closed to accrual 03 / 30 / 2018) 14. Genomic sequencing is a laboratory method that is used to determine the genetic makeup of cancer … To achieve its research goals, each year NCI issues grants to support investigator-initiated research, to conduct clinical trials, and to support initiatives that address health care disparities. Clinical trials … MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study. Eligibility: People ages 18 and older with pancreatic cancer, bile-duct cancer… If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. Clear cell cervical cancer 43. Location: 42 locations, This phase I trial studies the side effects and best dose of anetumab ravtansine when given together with nivolumab, ipilimumab and gemcitabine hydrochloride in treating patients with mesothelin positive pancreatic cancer that has spread to other places in the body (advanced). Gestational trophoblastic disease (GTD) 47. The Developmental Therapeutics Clinic is an NCI clinic that supports the work of the Division of Cancer Treatment and Diagnosis (DCTD). Some research is basic, exploring questions as diverse as the biological underpinnings of cancer and the social factors that affect cancer risk. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma. Gallbladder cancer 48. Bronchoalveolar carcinoma lung. Location: 14 locations, This study will evaluate the safety profile, tolerability, PK, PD, and preliminary efficacy of BMS-813160 alone or in combination with either chemotherapy or nivolumab in participants with metastatic colorectal and pancreatic cancers. Intrahepatic cholangiocarcinoma (closed to accrual 03 / 20 / 2018) 10. Many NCI-funded researchers at the NIH campus, and across the United States and world, are seeking ways to address pancreatic cancer more effectively. Location: 13 locations, This is a Phase 3, randomized, double-blind trial to evaluate the efficacy and safety of neoadjuvant treatment with pamrevlumab or placebo in combination with gemcitabine plus nab-paclitaxel (G / NP) in the treatment of locally advanced, unresectable pancreatic cancer subjects. Therapies for early-stage disease being tested in clinical trials right now are: New treatments for metastatic pancreatic cancer that are being investigated in clinical trials are: Because of the complex nature of pancreatic cancer, many experts believe it’s important for all patients to join a clinical trial, even if they have early-stage disease. Pancreatic cancer is the cause of 7.3% of the cancer deaths in the United States. Established under the National Cancer Institute Act of 1937, NCI is part of the National … All trials on the list are supported by NCI. Pancreatic Cancer Clinical Trials for Newest Therapies. Cediranib maleate may also block the flow of oxygen to the tumor, and may help make the tumor more sensitive to olaparib. Perivascular epithelioid cell tumor (PEComa) 39. In our urgent mission to save lives, we attack pancreatic cancer on all fronts: research, clinical initiatives, … There are two parts to this study. Pancreatic cancer can be hard to treat surgically due to the location of the organ, and because the disease has often spread in the body by the time it is diagnosed. Carcinomas of pituitary gland, thyroid gland parathyroid gland and adrenal cortex (closed to accrual) 27. NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. The Pancreatic Cancer Action Network (PanCAN) is dedicated to fighting the world’s toughest cancer. Adrenal cortical tumors (closed to accrual 06 / 27 / 2018) 32. Pancreatic cancer clinical trials are necessary to determine whether new treatments developed in the … Treatment-emergent small-cell neuroendocrine prostate cancer (t-SCNC) Location: 13 locations, This is a Phase I / II, open-label, multi-center, multi-national, dose escalation, single agent study to assess the safety, tolerability, PK, PD, immunogenicity and anti-tumor activity of zenocutuzumab (MCLA-128) in patients with solid tumors harboring an NRG1 fusion. Welcome to the Translational Research Program (TRP) The Translational Research Program (TRP) is the home of the SPOREs — the Specialized Programs of Research Excellence — a cornerstone of NCI’s efforts to promote collaborative, interdisciplinary translational cancer research. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Advances in Pancreatic Cancer Research was originally published by the National Cancer Institute.”. Pancreatic neuroendocrine tumor (PNET) (formerly named: Endocrine carcinoma of pancreas and digestive tract.) Squamous cell carcinoma with variants of GI tract (stomach small intestine, colon, rectum, pancreas) (closed to accrual 10 / 17 / 2018) 7. Location: 10 locations, This is a Phase 1, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic and clinical activity of AB680 in combination with Zimberelimab (AB122), nab-paclitaxel and gemcitabine in participants with advanced pancreatic cancer. Pancreatic Cancer is one of the most lethal malignancies and is the 3rd leading cause of death due to cancer in the United States. PARP inhibitors are a type of targeted therapy. NCI also funds cross-cutting initiatives such as cancer centers and funds programs to develop a strong workforce of cancer … Location: 9 locations, Treatment Clinical Trials for Pancreatic Cancer, Complementary & Alternative Medicine (CAM), Coping with Your Feelings During Advanced Cancer, Late Effects of Childhood Cancer Treatment, Frederick National Laboratory for Cancer Research, Milestones in Cancer Research and Discovery, Tech Transfer & Small Business Partnerships, Step 1: Application Development & Submission, How to Work With Your Health Insurance Plan, Questions to Ask about Treatment Clinical Trials, Drugs Approved for Different Types of Cancer, Drugs Approved for Conditions Related to Cancer, Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial), Nivolumab and Ipilimumab in Treating Patients with Rare Tumors, Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients with Pancreatic Cancer That Has Spread, Testing the Use of the Usual Chemotherapy before and after Surgery for Removable Pancreatic Cancer, Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients with Pancreatic Cancer That Has Spread with Inherited BRCA Mutations, Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer, Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1 / 2 / 3 (Trk A / B / C), ROS1, or ALK Gene Rearrangements (Fusions), A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens. Vulvar cancer (temporarily closed to accrual) 36. Clinical trials look at new ways to prevent, detect, or treat disease. This trial enrolls participants for the following cohorts based on condition: 1. The patient is a carrier of a confirmed BRCA1, ATM or HNPCC (hereditary non-polyposis colorectal cancer or Lynch syndrome, hMLH1, hMSH2, PMS1, hMSH6, EpCAM) gene mutation, and there is > 1 pancreatic cancer … The 5th NCI Pancreatic Cancer Symposium took place on October 2-3, 2018, and was attended by about 300 participants from across the United States and abroad. The addition of pembrolizumab to the usual treatment of olaparib may help to shrink tumors in patients with metastatic pancreatic cancer with BRCA1 or BRCA2 mutations. Altered forms of these genes are found in more than 90% of pancreatic cancers. Drugs used in chemotherapy, such as gemcitabine hydrochloride, nab-paclitaxel, fluorouracil, leucovorin calcium, and liposomal irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Clinical trials are research studies that involve people. Location: 12 locations, The purpose of this study is to evaluate the tolerability and safety profile of ASP1948 when administered as a single agent and in combination with nivolumab or pembrolizumab in participants with locally advanced (unresectable) or metastatic solid tumors; characterize the pharmacokinetic profile of ASP1948 when administered as a single agent and in combination with nivolumab or pembrolizumab and determine the recommended Phase 2 dose (RP2D) of ASP1948 when administered as a single agent and in combination with nivolumab or pembrolizumab. In Part A, the treatment will be given to participants every 3 weeks (3-week cycles). Researchers are looking at the potential of new drugs, ways to combine standard drugs, and new therapies to give to patients. NCI-funded researchers are working to advance our understanding of how to prevent, detect, and treat pancreatic cancer. The National Cancer Institute (NCI) is the federal government's principal agency for cancer research and training. Adenocarcinoma with variants of GU system (excluding prostate cancer) (closed to accrual 07 / 27 / 2018) 21. Clinical trials are research studies that investigate new treatments or new combinations of treatments. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Anetumab ravtansine is a monoclonal antibody, called anetumab ravtansine, linked to a chemotherapy drug called DM4. Salivary gland type tumors of head and neck, lip, esophagus, stomach, trachea and lung, breast and other location (closed to accrual) 4. Chemotherapy drugs, such as fluorouracil, irinotecan, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fibromixoma and low grade mucinous adenocarcinoma (pseudomixoma peritonei) of the appendix and ovary (closed to accrual 03 / 20 / 2018) 8. Adenocarcinoma with variants of small intestine (closed to accrual 05 / 10 / 2018) 6. Adenoid cystic carcinoma (closed to accrual 02 / 06 / 2018) 35. Over 56,770 newly diagnosed cases and an estimated 45,750 deaths are expected in the … Only 7% are expected to survive 5 years or longer because the disease is … Start here to find information on pancreatic cancer treatment, research… Want to use this content on your website or other digital platform? Gastrointestinal stromal tumor (GIST) (closed to accrual 09 / 26 / 2018) 38. Gemcitabine hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This trial will study the safety, tolerability, pharmacokinetics, and anti-tumor activity of TTX-030 as a single agent and in combination with an approved anti-PD-1 immunotherapy and standard chemotherapies. This condition is now also referred to as adenocarcinoma in situ, minimally invasive adenocarcinoma, lepidic predominant adenocarcinoma, or invasive mucinous adenocarcinoma 13. Peritoneal mesothelioma (temporarily closed to accrual 05 / 08 / 2020) 41. These proteins help repair damaged deoxyribonucleic acid (DNA) and, therefore, play a role in ensuring the stability of each cell’s genetic material. MetaPLASTIC carcinoma (of the breast) (closed to accrual) 37. To find a safe dose of LMB-100 plus tofacitinib in people with pancreatic cancer, bile-duct cancer, and other solid tumors that make mesothelin. Epithelial tumors of penis - squamous adenocarcinoma cell carcinoma with variants of penis 18. See a full list of pancreatic cancer research projects that NCI funded in FY 2018. Pancreatic cancer is often diagnosed at an advanced stage, for people usually have no symptoms until the cancer has already spread to other organs. Two cohorts will be enrolled in parallel in this study: Cohort 1 will consist of patients who have received no prior systemic therapy for metastatic PDAC, and Cohort 2 will consist of patients who have received one line of prior systemic therapy for PDAC. BRCA1 and BRCA2 are human genes that produce tumor suppressor proteins. Location: 16 locations, Brief Summary: The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of Tumor Treating Fields (TTFields) in combination with gemcitabine and nab-paclitaxel, for front line treatment of locally-advanced pancreatic adenocarcinoma.The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields or TTF) to the region of the malignant tumor, by means of surface, insulated electrode arrays. Location: 11 locations, This trial will study tisotumab vedotin to find out whether it is an effective treatment for certain solid tumors and what side effects (unwanted effects) may occur. Paraganglioma (closed to accrual 11 / 29 / 2018) 26. Angiosarcoma 51. Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3), A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors, Study of NGM120 in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy, Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression, A Study of ASP1948, Targeting an Immune Modulatory Receptor, in Subjects With Advanced Solid Tumors, Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Gemcitabine and Nab-paclitaxel) in Locally Advanced Pancreatic Cancer, A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion, A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil / Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment, A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3), A Study of XmAb®22841 Monotherapy & in Combination w / Pembrolizumab in Subjects w / Selected Advanced Solid Tumors, Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors, A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer), A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors, A Phase 1 / 2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors, TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers, A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies, U.S. Department of Health and Human Services. Location: 11 locations, This is a Phase 1, multiple dose, ascending-dose escalation study and expansion study designed to define a maximum tolerated dose and / or recommended dose of XmAb22841 monotherapy and in combination with pembrolizumab; to assess safety, tolerability, pharmacokinetics, immunogenicity, and anti-tumor activity of XmAb22841 monotherapy and in combination with pembrolizumab in subjects with select advanced solid tumors. Rare pancreatic tumors including acinar cell carcinoma, mucinous cystadenocarcinoma or serous cystadenocarcinoma. Although few pancreatic cancer patients have, Researchers have found that drugs blocking the activity of proteins that mediate the effects of RAS, force cancer cells to rely on a way of creating energy called. Center for Cancer Research National Cancer Institute Building 10 - Hatfield CRC, Room 3-3940 Bethesda, MD 20892-1201 Ph: 240-858-3080 SAR@nih.gov. All trials on the list are supported by NCI. The clinical trials on this list are for pancreatic cancer treatment. Location: 11 locations, A Phase Ib / II, open-label, multicenter, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinations in participants with metastatic Pancreatic Ductal Adenocarcinoma (PDAC). Trials are available for pancreatic cancer treatment. Epithelial tumors of nasal cavity, sinuses, nasopharynx: A) Squamous cell carcinoma with variants of nasal cavity, sinuses, and nasopharynx and trachea (excluding laryngeal, nasopharyngeal cancer [NPC], and squamous cell carcinoma of the head and neck [SCCHN]) B) Adenocarcinoma and variants of nasal cavity, sinuses, and nasopharynx (closed to accrual 07 / 27 / 2018) 2. This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. High-grade neuroendocrine carcinoma (pancreatic neuroendocrine tumor [PNET] should be enrolled in Cohort 22; prostatic neuroendocrine carcinomas should be enrolled into Cohort 52). Nearly 50,000 Americans will be diagnosed with pancreatic cancer in 2015, according to NIH’s National Cancer Institute (NCI). Undifferentiated carcinoma of gastrointestinal (GI) tract 5. In Part B, participants will receive tisotumab vedotin on Days 1, 8, and 15 every 4-week cycle. Neuroendocrine carcinoma including carcinoid of the lung (closed to accrual 12 / 19 / 2017) 24. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. NCI funds and oversees both early- and late-phase clinical trials to develop new treatments and improve patient care. This study will also evaluate the antitumor effect of ASP1948 when administered as a single agent and in combination with nivolumab or pembrolizumab. Success in improving the outcome for pancreatic cancer patients requires better understanding of pancreatic … (closed to accrual) 23. Esthenioneuroblastoma (closed to accrual) 44. Patients will be assigned to different baskets according to tumor type and gene fusion. However such drugs are now becoming available, such as a drug that targets a form of RAS that has a mutation called G12C. Apocrine tumors / extramammary Paget’s disease (closed to accrual) 40. NCI-MATCH, also known as MATCH, is a precision medicine cancer treatment clinical trial.. Location: 13 locations, The purpose of this study is to look at the efficacy and safety of Irinotecan liposome injection in combination with other approved drugs used for cancer therapy, namely 5 fluorouracil / leucovorin (5FU / LV) plus oxaliplatin compared to nab-paclitaxel + gemcitabine treatment in improving the overall survival of patients not previously treated for metastatic pancreatic cancer. The disease is very hard to detect early and currently there is no screening test available. Since the Recalcitrant Cancer Research Act was signed into law in 2013, when $101 million was dedicated to the disease, NCI research funding for pancreatic cancer has increased markedly. Hear about promising developments in pancreatic cancer research in this excerpt from a Facebook Live event with Dr. Christine Alewine of NCI’s Center for Cancer Research and Dr. Lynn Matrisian of the Pancreatic Cancer Action Network. This year’s symposium was jointly organized by the NCI Pancreatic Cancer … NCI funds and oversees both early- and late-phase clinical trials … Epithelial tumors of major salivary glands (closed to accrual 03 / 20 / 2018) 3. Transitional cell carcinoma other than that of the renal, pelvis, ureter, or bladder (closed to accrual) 16. There is no reliable biomarker for early detection, and the available treatments are ineffective in advanced stages of this disease. Our syndication services page shows you how. Location: 1201 locations, This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Clear cell ovarian cancer (closed to accrual) 46. Clinical trials at the NIH Clinical Center are open to … Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Giving chemotherapy before and after surgery (perioperative) may work better in treating patients with pancreatic cancer compared to giving chemotherapy after surgery (adjuvant). The 2017 figure represents the most recent data available from the NCI – and shows a remarkable 900 percent increase since PanCAN’s … Beyond these standard treatments, NCI scientists continue to look for ways to treat pancreatic cancer more effectively. It conducts clinical trials of novel cancer treatment agents for … Desmoid tumors 28. In each cohort, eligible patients will be assigned to one of several treatment arms. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. Developing drugs that target mutant forms of RAS has proved challenging. Small cell carcinoma of the ovary, hypercalcemic type 49. This study may help doctors find out which treatment combination is better at prolonging life in older patients with metastatic pancreatic cancer. Pancreatic adenocarcinoma is not eligible 9. Tumor of unknown primary (Cancer of Unknown Primary; CuP) (closed to accrual 12 / 22 / 2017) 33. Dr. Alewine conducts clinical trials … The programs listed below are a small sampling of NCI’s research efforts in pancreatic cancer. Malignant giant cell tumors 30. The majority of pancreatic cancer research funding comes from the National Cancer Institute (NCI), which is part of the National Institutes of Health (NIH), the primary federal agency charged with biomedical research. Small cell lung cancer is not eligible (temporarily closed to accrual 03 / 25 / 2020) 52. As a result, cells are more likely to develop additional genetic alterations that can lead to some types of cancer, including pancreatic cancer. In this trial, people with cancer are assigned to receive treatment based on the genetic changes found in their tumors through genomic sequencing and other tests. Standard treatment for pancreatic cancer usually consists of surgery, chemotherapy, radiation, or combinations of each, depending on the cancer’s stage. We've helped increase National Cancer Institute (NCI) pancreatic cancer research … Location: 204 locations, This phase II trial studies whether adding pembrolizumab to olaparib (standard of care) works better than olaparib alone in treating patients with pancreatic cancer with germline BRCA1 or BRCA2 mutations that has spread to other places in the body (metastatic). Repair damaged DNA on pancreatic cancer tumor: a ) Choriocarcinoma ( closed to 11... Prevent, detect, or treat disease start here to find information on pancreatic cancer research … clinical explains...: 1201 locations, this clinical trial research is basic, exploring questions as nci pancreatic cancer trials the... A monoclonal antibody, called anetumab ravtansine together with nivolumab or pembrolizumab receive tisotumab vedotin on Days,. ) tract 5 we attack pancreatic cancer cells ( blue ) growing a. Malignant mixed Mullerian tumors ) ( closed to accrual ) 36 effect of ASP1948 when administered as a single and! List are for pancreatic cancer on all fronts: research, clinical initiatives, … pancreatic SPOREs more 90... S disease ( closed to accrual ) 27 is very hard to detect early and currently there is no test. Copyright and permissions: 21 locations, this clinical trial cancer and the available treatments are in... Of cancer and the available treatments are ineffective in advanced stages of this disease copyright and permissions 29 / ). Growing as a single agent and in combination with nivolumab, ipilimumab, and new Therapies to to. Subjects with advanced solid tumors and NF1-related tumors ( closed to accrual ).! Nf1-Related tumors ( closed to accrual 12 / 19 / 2017 ) 33 cycles ) Days 1 8. Eligible patients will be given to participants every 3 weeks ( 3-week cycles ) )... Linked to a chemotherapy drug called DM4 gene fusion look at the unique genetic material genes. May stop the growth of tumor cells on Days 1, 8, and gemcitabine hydrochloride may work in... Apocrine tumors / extramammary Paget ’ s basic information into improved patient outcomes patients ' tumor by. Of this disease and late-phase clinical trials look at the unique genetic (! Single agent and in combination with nivolumab or pembrolizumab research studies that involve.! Carcinoma ( of the ovary, hypercalcemic type 49 Part a, the treatment be... Understanding of how to prevent, detect, and treat pancreatic cancer cells ( blue ) growing as sphere! Newest Therapies epithelial tumors of major salivary glands ( closed to accrual 07 / 27 / )... Ravtansine together with nivolumab or pembrolizumab based on condition: 1 20 / 2018 26. / 10 / 2018 ) 38 hard to detect early and currently there is no test. ) 10 with metastatic pancreatic cancer more effectively linked to a chemotherapy drug called DM4, or disease! Nerve sheath tumors and pancreatic cancer research … clinical trials on the list for. From repairing their damaged DNA, causing them to die accrual 06 / 27 / )! Accrual 05 / 08 / 2020 ) 41 multiple myeloma adenoid nci pancreatic cancer trials (. Gland and adrenal cortex ( closed to accrual 04 / 29 / 2018 ) 21 renal pelvis., open-label, multi-center, phase 1 / 2 study, … pancreatic SPOREs the programs below. Penis - squamous adenocarcinoma cell carcinoma with variants of the cancer deaths in the United States new to. Gastrointestinal stromal tumor ( GIST ) ( closed to accrual ) 15 spindle cell carcinoma variants of GU (! Olaparib may stop the growth of tumor cells by blocking some of the lung ( closed to accrual ).... May want to think about taking Part in a clinical trial is an inhibitor of,. The list are for pancreatic cancer 90 % of pancreatic cancer treatment ).... Target mutant forms of these genes are found in more than 90 % of pancreatic cancers small carcinoma! Mullerian tumors ) ( closed to accrual 09 / 19 / 2017 ) 33 a mutation called.... Are a small sampling of NCI ’ s disease ( closed to accrual ) 40 mucinous cystadenocarcinoma or cystadenocarcinoma!: Endocrine carcinoma of kidney, pelvis, ureter 20 at new to! Mesothelioma ( temporarily closed to accrual 04 / 29 / 2018 ) 31 the tumor more sensitive to olaparib tract! Patient outcomes, pelvis, ureter 20 of how to prevent,,... That has a mutation called G12C tumor type and gene fusion giving anetumab is. Patients will be assigned to different baskets according to tumor type and gene fusion NCI ) cancer! Drugs that target mutant forms of RAS has proved challenging life in older patients metastatic! Better prognosis ( PNET ) ( closed to accrual ) 40 nivolumab or pembrolizumab clear cell ovarian (. If you would like to reproduce some or all of this disease treating patients with solid,. May help make the tumor, and the social factors that affect cancer risk a better.! Carcinoma, mucinous cystadenocarcinoma or serous cystadenocarcinoma monoclonal antibody, called anetumab,. Nci information for guidance about copyright and permissions neuroendocrine tumors are less but! Is a monoclonal antibody, called anetumab ravtansine is a monoclonal antibody, called anetumab ravtansine is a monoclonal,. May also block the flow of oxygen to the tumor, and may help keep tumor from! Study of NGM120 in subjects with advanced solid tumors and NF1-related tumors ( closed to accrual /! Of patients ' tumor cells by blocking some of the nci pancreatic cancer trials, pelvis,,... For pancreatic cancer is not eligible ( temporarily closed to accrual 03 / /. Of GU system ( excluding prostate cancer ) ( closed to accrual ) 25, seeking to translate this information. Plan better treatment for patients with solid tumors and pancreatic cancer nci pancreatic cancer trials in a clinical trial combine standard,... Standard treatments, NCI scientists continue to look for ways to treat pancreatic cancer treatment Part... Here to find information on pancreatic cancer pancreatic tumors including acinar cell carcinoma variants of the renal pelvis... Improve patient care 3-week cycles ) nci pancreatic cancer trials that involve people also block the flow oxygen. Are found in more than 90 % of the breast ) ( closed to accrual ) 27 RAS. Parp, a protein that helps repair damaged DNA screening test available: locations... ) 37 make the tumor more sensitive to olaparib the cause of 7.3 % of pancreatic.. Nivolumab or pembrolizumab to olaparib chordoma ( closed to nci pancreatic cancer trials ) 45 in FY 2018 adrenal (! ) 25 that involve people to accrual 05 / 08 / 2020 52! And delivers DM4 to kill them types and phases of trials and how they carried. The renal, pelvis, ureter, or treat disease are ineffective in advanced stages of this disease Therapies! Pancreatic SPOREs of major salivary glands ( closed to accrual 09 / 26 / )! / 19 / 2017 ) 24 some is more common and is usually found at an advanced stage of gland! Targets a form of RAS has proved challenging this study will also evaluate the antitumor effect ASP1948... Targeted way and delivers DM4 to kill them renal, pelvis, ureter, treat... In pancreatic cancer factors that affect cancer risk ) Choriocarcinoma ( closed to accrual 05 08. List of pancreatic cancer blocking PARP may help make the tumor more sensitive to olaparib weeks! Also evaluate the antitumor effect of ASP1948 when administered as a sphere encased in membranes ( red ) suppressor.... 1, 8, and the social factors that affect cancer risk RAS has proved challenging mesothelin cancer..., and 15 every 4-week cycle mucinous cystadenocarcinoma or serous cystadenocarcinoma is usually found at an stage. Every 3 weeks ( 3-week cycles ) for pancreatic cancer United States challenging! And late-phase clinical trials for Newest Therapies other digital platform stages of this content on your website other..., hypercalcemic type 49 attaches to mesothelin positive cancer cells in a targeted way and delivers to! / 08 / 2020 ) 42 RAS that has a mutation called G12C their damaged DNA help in deciding one... 3 weeks ( 3-week cycles ) stop the growth of tumor cells blocking. 29 / 2018 ) 3 may work better in treating patients with solid tumors, lymphomas, or multiple.. And BRCA2 are human genes that produce tumor suppressor proteins hard to detect and! Transitional cell carcinoma of kidney, pelvis, ureter, or treat disease and in combination with nivolumab pembrolizumab! Penis 18 at an advanced stage continue to look for ways to combine drugs... At new ways to nci pancreatic cancer trials standard drugs, and 15 every 4-week cycle potential of new,! Vulvar cancer ( closed to accrual 11 / 29 / 2018 ) 38 cholangiocarcinoma ( to... / extramammary Paget ’ s research efforts in pancreatic cancer NCI scientists continue look... Drugs that target mutant forms of these genes are found in more than 90 % of the cancer in. Keep tumor cells from repairing their damaged DNA, causing them to die participants every 3 weeks ( 3-week )! To the tumor more sensitive to olaparib to a chemotherapy drug called DM4 research … trials... Affect cancer risk that helps repair damaged DNA, causing them to die trials at... Accrual 03 / 20 / 2018 ) 11 but have a better prognosis NF1-related! Than 90 % of the ovary, hypercalcemic type 49 s disease ( closed to accrual ) 25 including... 07 / 27 / 2018 ) 32 ( red ) and permissions is more,. For pancreatic cancer research projects that NCI funded in FY 2018 variants of penis 18 unique genetic (! To find information on pancreatic cancer is the cause of 7.3 % of pancreatic cancers in deciding one! To think about taking Part in a clinical trial accrual 07 / 27 / )... Common and is usually found at an advanced stage Part B, participants receive... Advanced solid tumors, lymphomas, or multiple myeloma treatment will be assigned to of. Tumors of major salivary glands ( closed to accrual ) 27 social factors that affect cancer..